Elcelyx (“L-cell-ix”) was founded in 2010 to advance Gut Sensory Modulation (GSM) technology, based on the elucidation that enteroendocrine cells located in the lining of the lower gut can be modulated locally to elicit systemic physiological and pharmacological effects. This discovery affords a potentially safety-advantaged platform to develop novel therapies as well as re-position existing therapies to meet serious unmet needs. Metformin DR (metformin delayed-release) is Elcelyx’s lead product candidate, currently in Phase 2b development as a potential agent uniquely suited for patients who cannot currently use metformin owing to contraindications or poor tolerability.